Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Molecular diagnostics of lung cancer in the clinic

Sholl, L. M. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.08.03 · Cited by 56

Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status

Xiao, Z., Sperl, B., Ullrich, A., & Knyazev, P. G. (2014) · Oncotarget · doi:10.18632/oncotarget.2657 · Cited by 55

N-glycans of growth factor receptors: their role in receptor function and disease implications

Takahashi, M., Hasegawa, Y., Gao, C., Kuroki, Y., & Taniguchi, N. (2016) · Clinical Science · doi:10.1042/cs20160273 · Cited by 56

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

John, T., Akamatsu, H., Delmonte, A., Su, W., Lee, J. S., Chang, G., Huang, X., Jenkins, S. C., & Wu, Y.-L. L. C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.027 · Cited by 55

ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition

Toulany, M., Minjgee, M., Saki, M. R., Holler, M., Meier, F. E., Eicheler, W., & Rodemann, H. P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.27311 · Cited by 55

The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants

Chung, B., Dimri, M., George, M. E., Reddi, A. L., Chen, G.-S., Band, V., & Band, H. (2009) · Oncogene · doi:10.1038/onc.2009.31 · Cited by 62

From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway

Cardó‐Vila, M., Giordano, R. J., Sidman, R. L., Bronk, L. F., Fan, Z., Mendelsohn, J. M., Arap, W., & Pasqualini, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915146107 · Cited by 56

Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands

Falivelli, G., Lisabeth, E. M., de la Torre, E. R., Pérez‐Tenorio, G., Tosato, G., Salvucci, O., & Pasquale, E. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081445 · Cited by 58

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

Ayoola, A., Barochia, A., Belani, K., & Belani, C. P. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.666691 · Cited by 56

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line

Tang, Z.-H., Jiang, X., Guo, X., Fong, C. M. V., Chen, X., & Lu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13150 · Cited by 56

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance

Zhang, Y., Xiang, C., Wang, Y., Duan, Y., Liu, C., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21328 · Cited by 55

Heterogeneity in Malignant Pleural Mesothelioma

Oehl, K., Vrugt, B., Opitz, I., & Meerang, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061603 · Cited by 55

CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis

Hu, X., Zhao, Y., Wei, L., Zhu, B., Song, D., Wang, J., Yu, L., & Wu, J. (2017) · Oncogene · doi:10.1038/onc.2017.10 · Cited by 54

Epiregulin as a therapeutic target in non-small-cell lung cancer

Sunaga, N., & Kaira, K. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s60427 · Cited by 55

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

Haratake, N., Ozawa, H., Morimoto, Y., Yamashita, N., Daimon, T., Bhattacharya, A., Wang, K., Nakashoji, A., Isozaki, H., Shimokawa, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.017 · Cited by 54

Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells

Chiu, H.-C., Chou, D.-L., Huang, C.-T., Lin, W., Lien, T., Yen, K.-J., & Hsu, J. T.-A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.003 · Cited by 56

Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma

Masago, K., Asato, R., Fujita, S., Hirano, S., Tamura, Y., Kanda, T., Mio, T., Katakami, N., Mishima, M., & Ito, J. (2008) · International Journal of Cancer · doi:10.1002/ijc.24250 · Cited by 54

Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1

Wang, S., Liu, S., Zhao, B., Yang, F., Wang, Y.-T., Liang, Q., Sun, Y., Liu, Y., Song, Z., Cai, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4536 · Cited by 56

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer

Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D. A., Rakiec, D. P., Korn, J. M., McAllister, G., Stegmeier, F. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 56

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR

Decraene, C., Silveira, A. B., Bidard, F., Vallée, A., Michel, M., Melaabi, S., Vincent‐Salomon, A., Saliou, A., Houy, A., Milder, M., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272518 · Cited by 54

Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs

Zhang, H., Wang, J., Shen, Y. H., Wang, H., Duan, W.-M., Zhao, H., Hei, Y., Xin, M., Cao, Y., & Zhang, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.051 · Cited by 54

Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case

Roca, E., Pozzari, M., Vermi, W., Tovazzi, V., Baggi, A., Amoroso, V., Nonnis, D., Intagliata, S., & Berruti, A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.016 · Cited by 54

Identification of genetic alterations associated with primary resistance to EGFR‐TKIs in advanced non‐small‐cell lung cancer patients with EGFR sensitive mutations

Wang, F., Diao, X., Zhang, X., Shao, Q., Feng, Y., An, X., & Wang, H. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0354-z · Cited by 54

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

van Rosenburgh, I. K. V. A., Lu, D. M., Grant, M. J., Stayrook, S. E., Phadke, M. A., Walther, Z., Goldberg, S. B., Politi, K. A., Lemmon, M. A., Ashtekar, K. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34398-z · Cited by 53

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer

Douillard, J., Pirker, R., O'Byrne, K. J., Kerr, K. M., Störkel, S., von Heydebreck, A., Grote, H. J., Celik, I., & Shepherd, F. A. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000141 · Cited by 53

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

Haspinger, E. R., Agustoni, F., Torri, V., Gelsomino, F., Platania, M., Zilembo, N., Gallucci, R., Garassino, M. C., & Cinquini, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.11.005 · Cited by 56

Chromosomal and genomic changes in lung cancer

Varella‐Garcia, M. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10884 · Cited by 53

Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR–Cysteine 797 andN-(4-Anilinoquinazolin-6-yl) Acrylamide

Capoferri, L., Lodola, A., Rivara, S., & Mor, M. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500720e · Cited by 53

Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer

López‐Ríos, F., Angulo, B., Gomez, B., Mair, D., Martínez, R., Conde, E., Shieh, F., Tsai, J., Vaks, J. E., Current, R., et al. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201240 · Cited by 53

Extracellular vesicles shed from gefitinib‐resistant nonsmall cell lung cancer regulate the tumor microenvironment

Choi, D., You, S., Jung, J. H., Lee, J. C., Rho, J. K., Lee, K. Y., Freeman, M. R., Kim, K. P., & Kim, J. (2014) · PROTEOMICS · doi:10.1002/pmic.201400008 · Cited by 54

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma

Han, J., Kim, S. H., Lee, Y.-S., Lee, S. Y., Hwang, J.-A., Kim, J. Y., Yoon, S. J., & Lee, G. K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.04.009 · Cited by 53

Why imatinib remains an exception of cancer research

Horne, S. D., Stevens, J. B., Abdallah, B. Y., Liu, G., Bremer, S. W., Ye, C. J., & Heng, H. H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24233 · Cited by 53

The Landscape of EGFR Pathways and Personalized Management of Non-Small-Cell Lung Cancer

Liang Cheng, C., Zhang, S., Alexander, R. E., Yao, Y., MacLennan, G. T., Pan, C.-X., Huang, J., Wang, M., Montironi, R., & Antonio Lopez-beltran, B. (2011) · Future Oncology · doi:10.2217/fon.11.25 · Cited by 53

Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer

Hu, R., Huffman, K. E., Chu, M., Zhang, Y., Minna, J. D., & Yu, Y. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00819 · Cited by 53

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy

Ding, C., Chen, S., Zhang, C., Hu, G., Zhang, W., Li, L., Chen, Y., Tan, C., & Jiang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.006 · Cited by 53

FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation

Elangovan, I., Vaz, M. J., Tamatam, C. R., Potteti, H. R., Reddy, N. M., & Reddy, S. P. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0164oc · Cited by 53

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Masuzawa, K., Yasuda, H., Hamamoto, J., Nukaga, S., Hirano, T., Kawada, I., Naoki, K., Soejima, K., & Betsuyaku, T. (2017) · Oncotarget · doi:10.18632/oncotarget.22297 · Cited by 53

BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells

Bach, D., Luu, T.-T.-T., Kim, D., An, Y., Park, S., Park, H. J., & Lee, S. K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.016 · Cited by 53

Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer

Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 55

C-11 Radiochemistry in Cancer Imaging Applications

Tu, Z., & Mach, R. H. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791384261 · Cited by 53

A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives

do Amaral, D. N., Lategahn, J., Fokoue, H. H., da Silva, E. M. B., Sant’Anna, C. M. R., Rauh, D., Barreiro, E. J., Laufer, S., & Lima, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-018-36846-7 · Cited by 52

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision

SOUSA, A. M. D., Silveira, C., Janeiro, A., Malveiro, S., Oliveira, A. R., Felizardo, M., Nogueira, F., Teixeira, E., Martins, J., & Carmo‐Fonseca, M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.030 · Cited by 52

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

Yao, N., Wang, C., Liu, M., Li, Y., Chen, W., Li, Z., Qi, Q., Lu, J., Fan, C.-L., Chen, M., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00251-2 · Cited by 53

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

Gomez, G. G., Wykosky, J., Zanca, C., Furnari, F. B., & Cavenee, W. K. (2013) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2013.04.003 · Cited by 53

Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

Jakobsen, J. N., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1791-9 · Cited by 52

High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications

Ocak, S., Sos, M. L., Thomas, R. K., & Massion, P. P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00042409 · Cited by 53

Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents

Meoni, G., Cecere, F. L., Lucherini, E., & Costanzo, F. D. (2013) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.04.005 · Cited by 52

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

Hanan, E. J., Baumgardner, M., Bryan, M. C., Chen, Y., Eigenbrot, C. W., Fan, P. W., Gu, X., La, H., Malek, S., Purkey, H. E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.078 · Cited by 52

Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor

Xu, X., Weng, X., Wang, C., Lin, W.-W., Liu, A., Chen, W., & Lin, X. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.02.009 · Cited by 52

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

Qian, X., Liu, J., Sun, Y., Wang, M., HuaiDing, L., Luo, G., Liu, X., Xiong, C., Liu, J., Liu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8684 · Cited by 52

Assessment of SRM, MRM3, and DIA for the targeted analysis of phosphorylation dynamics in non‐small cell lung cancer

Schmidlin, T., Garrigues, L., Lane, C. S., Mulder, T., van Doorn, S., Post, H., de Graaf, E. L., Lemeer, S., Heck, A. J. R., & Altelaar, M. A. F. (2016) · PROTEOMICS · doi:10.1002/pmic.201500453 · Cited by 53

Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3

Shou, J., You, L., Yao, J., Xie, J., Jing, J., Zhao, J., Jiang, L., Sui, X., Pan, H., & Han, W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.002 · Cited by 52

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Steen, N. V. D., Caparello, C., Rolfo, C. D., Pauwels, P., Peters, G. J., & Giovannetti, E. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s97644 · Cited by 55

Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature

How, J., Mann, J., Laczniak, A. N., & Baggstrom, M. Q. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.013 · Cited by 52

A Fast, Sensitive and Accurate High Resolution Melting (HRM) Technology-Based Assay to Screen for Common K-ras Mutations

Kramer, D., Thunnissen, E., Gallegos-Ruiz, M. I., Smit, E. F., Postmus, P. E., Meijer, C. J. L. M., Snijders, P. J. F., & Heideman, D. A. M. (2009) · Analytical Cellular Pathology · doi:10.1155/2009/159371 · Cited by 52

NCI's provocative questions on cancer: some answers to ignite discussion

Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.432 · Cited by 51

Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities

Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51

Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas

Dobashi, Y., Suzuki, S., Matsubara, H., Kimura, M., Endo, S., & Ooi, A. (2008) · Cancer · doi:10.1002/cncr.23996 · Cited by 51

Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development

Zieger, K., Marcussen, N., Borre, M., Orntoft, T. F., & Dyrskjøt, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24619 · Cited by 51

A quantum dot-based microRNA nanosensor for point mutation assays

Zeng, Y.-P., Zhu, G., Yang, X., Cao, J., Zhi-liang, J., & Zhang, C. (2014) · Chemical Communications · doi:10.1039/c4cc02034k · Cited by 51

Targeting the MET oncogene in cancer and metastases

Stella, G. M., Benvenuti, S., & Comoglio, P. M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.522988 · Cited by 52

Hedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinoma

Lin, E.-H., Kao, Y.-R., Lin, C.-A., Kuo, T.-Y., Yang, S., Hsu, C., Chou, T., Ho, C., & Wu, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8253 · Cited by 51

PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα

Dopeso, H., Jiao, H., Cuesta, Á. M., Henze, A., Jurida, L., Kracht, M., Acker‐Palmer, A., Garvalov, B. K., & Acker, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1346 · Cited by 52

Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma

Hasanovic, A., Ang, D. C., Moreira, A. L., & Zakowski, M. F. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.004 · Cited by 50

CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell

Song, Q., Yi, F., Zhang, Y., Li, D. K. J., Wei, Y., Yu, H., & Zhang, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5671-8 · Cited by 50

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation

Ruffilli, C., Röth, S., Rodrigo, M., Boyd, H., Zelcer, N., & Moreau, K. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00142 · Cited by 51

Graphene oxide-based biosensors for detection of lung cancer: A review

AL-Salman, H. N. K., Hsu, C., Jawad, Z. N., Mahmoud, Z. H., Mohammed, F., Saud, A., Al‐Mashhadani, Z. I., Hadal, L. S. A., & Kianfar, E. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101300 · Cited by 50

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment

Alsaed, B., Lin, L., Son, J., Li, J., Smolander, J., Lopez, T., Eser, P. Ö., Ogino, A., Ambrogio, C., Eum, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55378-5 · Cited by 51

Overcoming cancer therapy resistance: From drug innovation to therapeutics

Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 53

Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation

Li, M.-Y., Lai, P.-L., Chou, Y.-T., Chi, A.-P., Mi, Y.-Z., Khoo, K., Chang, G.-D., Wu, C.-W., Meng, T.-C., & Chen, G. (2014) · Oncogene · doi:10.1038/onc.2014.312 · Cited by 50

Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer

Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 52

Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Zhang, H., Liu, D., Li, S., Zheng, Y.-Q., Yang, X., Li, X., Zhang, Q., Qin, N., Lu, J., Ren‐Heidenreich, L., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.06.006 · Cited by 50

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

Amin, D. N., Sergina, N. V., Lim, L., Goga, A., & Moasser, M. M. (2012) · Biochemical Journal · doi:10.1042/bj20120724 · Cited by 50

Domain‐mediated protein interaction prediction: From genome to network

Reimand, J., Hui, S., Jain, S., Law, B., & Bader, G. D. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.027 · Cited by 53

Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling

Conte, A., & Sigismund, S. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.03.002 · Cited by 53

Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review

Perisanidis, C. (2017) · In Vivo · doi:10.21873/invivo.11020 · Cited by 50

Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA

Thongon, N., Zucal, C., D’Agostino, V., Tebaldi, T., Ravera, S., Zamporlini, F., Piacente, F., Moschoi, R., Raffaelli, N., Quattrone, A., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0174-7 · Cited by 51

Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9

Cheung, A. H. K., Chow, C., Zhang, J., Zhou, Y., Huang, T., Ng, K. C.-K., Or, T. C. T., Yao, Y. Y., Dong, Y., Fung, J. M.-W., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0056-1 · Cited by 50

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

Hasegawa, H., Yasuda, H., Hamamoto, J., Masuzawa, K., Tani, T., Nukaga, S., Hirano, T., Kobayashi, K., Manabe, T., Terai, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.039 · Cited by 50

Amplification-free SERS analysis of DNA mutation in cancer cells with single-base sensitivity

Wu, L., Garrido‐Maestu, A., Guerreiro, J. R. L., Carvalho, S., Abalde‐Cela, S., Prado, M., & Diéguez, L. (2019) · Nanoscale · doi:10.1039/c9nr00501c · Cited by 51

Comprehensive Mapping of the Human Kinome to Epidermal Growth Factor Receptor Signaling

Komurov, K., Padrón, D., Cheng, T., Roth, M. G., Rosenblatt, K. P., & White, M. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137828 · Cited by 50

CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma

Hu, F., Chen, H., Duan, Y., Lan, B., Liu, C., Hu, H., Xu, D., Zhang, Q., Cheng, Y., Liu, M., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.032 · Cited by 49

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents

Wang, C., Zhang, Y., Shi, L., Yang, S., Chang, J., Zhong, Y., Li, Q., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2074414 · Cited by 50

Highly Multiplexed Tissue Imaging in Precision Oncology and Translational Cancer Research

Bollhagen, A., & Bodenmiller, B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1165 · Cited by 55

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

Jadus, M. R., Natividad, J., Mai, A., Ouyang, Y. Q., Lambrecht, N. W. G., Szabó, S., Ge, L., Hoa, N. T., & Dacosta-Iyer, M. G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/160724 · Cited by 49

ERBB oncogene proteins as targets for monoclonal antibodies

Polanovsky, O. L., Lebedenko, E. N., & Deyev, S. M. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912030029 · Cited by 49

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

Sholl, L. M., Iafrate, A. J., Chou, Y.-P., Wu, M., Goan, Y., Su, L., Huang, Y., Christiani, D. C., & Chirieac, L. R. (2007) · Modern Pathology · doi:10.1038/modpathol.3800946 · Cited by 49

Pharmacogenetics of EGFR and VEGF inhibition

Pander, J., Gelderblom, H. A. J., & Guchelaar, H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.016 · Cited by 49

Targeting histone deacetylases for the treatment of disease

Lawless, M. W., Norris, S., O'Byrne, K. J., & Gray, S. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00571.x · Cited by 49

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

Wheatley‐Price, P., & Shepherd, F. A. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f335a3 · Cited by 49

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells

Sakuma, Y., Matsukuma, S., Nakamura, Y., Yoshihara, M., Koizume, S., Sekiguchi, H., Saito, H., Nakayama, H., Kameda, Y., Yokose, T., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.102 · Cited by 49

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors

Kancha, R. K., Peschel, C., & Duyster, J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182021f3e · Cited by 49

FrequentEGFRmutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis

Wu, S., Hu, F., Chang, Y., Lee, Y.-C., Yu, C., Chang, Y., Wu, J., Shih, J., & Yang, P. (2012) · European Respiratory Journal · doi:10.1183/09031936.00006912 · Cited by 49

RNA is favourable for analysingEGFRmutations in malignant pleural effusion of lung cancer

Tsai, T.-H., Su, K., Wu, S., Chang, Y., Luo, S., Jan, I., Yu, C., Yu, S.-L., Shih, J.-Y., & Yang, P. (2011) · European Respiratory Journal · doi:10.1183/09031936.00043511 · Cited by 50

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

Ikemura, S., Yasuda, H., Matsumoto, S., Kamada, M., Hamamoto, J., Masuzawa, K., Kobayashi, K., Manabe, T., Arai, D., Nakachi, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819430116 · Cited by 49

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant

Sueangoen, N., Tantiwetrueangdet, A., & Panvichian, R. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00407-1 · Cited by 49

Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)

Karnik, K. S., Sarkate, A. P., Tiwari, S. V., Azad, R., Burra, P. V. L. S., & Wakte, P. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104612 · Cited by 49

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer

Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 52

Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas

Dobashi, Y., Suzuki, S., Kimura, M., Matsubara, H., Tsubochi, H., Imoto, I., & Ooi, A. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.025 · Cited by 49

EGFR, the Lazarus target for precision oncology in glioblastoma

Lin, B., Ziebro, J. K., Smithberger, E., Skinner, K., Zhao, E., Cloughesy, T. F., Binder, Z. A., O’Rourke, D. M., Nathanson, D. A., Furnari, F. B., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac204 · Cited by 50

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156